Topic

Hemophilia

A collection of 2 issues

Sangamo Seeks New Partners for Hemophilia Treatment

Sangamo is actively seeking new partnerships to advance its innovative hemophilia treatment. Discover the company's strategic moves in the biopharma landscape.

Sangamo Reclaims Rights to Hemophilia Gene Therapy from Pfizer

Sangamo Therapeutics regains rights to giroctocogene fitelparvovec after Pfizer's successful Phase 3 trials, marking a pivotal shift in hemophilia gene therapy.